GLP-1 receptor agonists have quickly become a widely used therapy for type 2 diabetes and obesity. Their ability to stimulate insulin secretion is well established, but these drugs, like Semaglutide and Tirzepatide, also appear to produce longer-term improvements in pancreatic β-cell health.
These effects include increased insulin production and greater resistance to metabolic stress, suggesting GLP-1 signalling may trigger sustained changes in cellular function. Such adaptations typically arise through changes in gene expression. However, the molecular mechanisms linking GLP-1 receptor signalling to transcriptional regulation in β-cells remain poorly understood.
A new study1 investigates this by examining how prolonged GLP-1 signalling reshapes gene activity in pancreatic β-cells. The authors identify a regulatory protein, Med14, that connects GLP-1 signalling pathways with the transcriptional programs that support β-cell survival and insulin production.
To investigate how prolonged GLP-1 signalling alters gene activity, the researchers screened pancreatic β-cells for regulatory proteins that respond to sustained GLP-1 stimulation. Because GLP-1 receptor activation increases intracellular cAMP and activates protein kinase A (PKA), the team focused on identifying transcriptional regulators that are phosphorylated downstream of this pathway, using forskolin (FSK) to activate cAMP-PKA signalling in the screen.
Using an INS-1 pancreatic β-cell model, the researchers performed this proteomic screen using a phospho-PKA substrate antibody immunoprecipitation followed by mass spectrometry. The analysis identified Med14, a scaffolding subunit of the Mediator complex, a multi-protein regulator that links transcription factors to RNA polymerase II during gene expression.
Further experiments showed that GLP-1 signalling increased cAMP levels and activated PKA, which phosphorylated Med14 at Ser983, a conserved regulatory site. This modification was required for the full transcriptional response to GLP-1 stimulation. When the phosphorylation site was mutated (Med14 S983A), the gene expression changes normally induced by GLP-1 exposure were largely abolished, but global transcription was relatively unaffected, suggesting Med14 acts selectively on a subset of genes involved in metabolism, ER stress, and insulin secretion.
The researchers confirmed this effect in both cultured pancreatic β-cells and in primary islets isolated from whole-body knock-in mice carrying the Med14 S983A mutation. In these models, disruption of Med14 phosphorylation impaired GLP-1–dependent transcriptional responses, indicating that Mediator activity is required for the downstream gene expression changes triggered by GLP-1 receptor signalling.
Together, these findings identify Med14 as a molecular link between GLP-1 receptor signalling and the transcriptional machinery that regulates gene activity in pancreatic β-cells.
These findings provide a mechanistic explanation for how GLP-1 receptor signalling produces longer-term effects in pancreatic β-cells. The identification of Med14 phosphorylation places the Mediator complex at the centre of this process. The Mediator complex is a key component of the transcriptional machinery, integrating signals from transcription factors and regulatory proteins to control RNA polymerase II activity across the genome.
By showing that GLP-1 signalling modified a core Mediator subunit through the cAMP-PKA pathway, this study connects hormone signalling directly to the transcriptional systems that regulate cellular function. Specifically, Med14 phosphorylation was found to promote gene expression by activating CREB-bound enhancers, genomic regulatory regions where CREB and Med14 appear to act cooperatively following their phosphorylation by PKA.
This mechanism also helps explain how GLP-1 receptor agonists can produce durable changes in β-cell physiology. Rather than acting only through short-term signalling events, the pathways described in this study alter gene expression patterns that influence β-cell survival and insulin production. Knock-in mice carrying the Med14 S983A mutation showed a reduction in β-cell numbers, an increase in α- and Δ-cells, and a shift in islet cell composition resembling that observed in type 2 diabetes. In this way, GLP-1 signalling may help alter the transcriptional landscape of pancreatic β-cells in response to metabolic demand.
This study adds to a growing effort to understand how GLP-1 receptor agonists produce effects that extend beyond immediate insulin activity. Clinical studies have shown that these therapies can improve metabolic control and reduce the risk of cardiovascular complications in people with type 2 diabetes. However, fully explaining these broader benefits requires a clearer understanding of how sustained GLP-1 signalling alters cellular behaviour.
By linking GLP-1 receptor activation to phosphorylation of Med14 at Ser983, this work highlights a route through which hormonal signals can influence genome-wide transcriptional regulation. Because the Mediator complex integrates signals from many transcription factors, similar mechanisms could operate in other metabolically active tissues that respond to cAMP signalling. Notably, the study confirmed that Med14 phosphorylation and downstream gene induction were similarly triggered by GLP-1 receptor agonists Semaglutide and Tirzepatide, strengthening the relevance of these findings to current therapeutic practice.
Several questions remain. The experiments in this study were conducted in cultured pancreatic β-cell lines and mouse models, and further work will be needed to confirm whether the same regulatory pathways operate in human pancreatic tissue. Future studies may also examine whether Med14 phosphorylation contributes to the broader physiological effects associated with GLP-1 therapies in organs such as the liver, adipose tissue, or muscle.
As interest in GLP-1 drugs continues to expand, defining the transcriptional mechanisms that connect receptor signalling to longer-term cellular adaptation will be important for understanding both their therapeutic benefits. Although these drugs have shown clear metabolic advantages, clinical studies also report adverse effects, most commonly gastrointestinal symptoms, such as nausea and vomiting, as well as other potential complications that continue to be investigated2. Understanding how GLP-1 signalling reshapes cellular gene activity may therefore also help explain the broader physiological responses they produce.